Objectif LT CMCIC 196 ! cours 24
Cours temps réel: 3,13 -1,73%| Cours | Graphes | News | Analyses et conseils | Société | Historiques | Vie du titre | Secteur | Forum |
CIC provides liquidity on Genfit. CIC provides
Investors marketing services to Genfit. Crédit Mutuel-
CM11 Group holds over 0,5% of GENFIT. CIC has
signed a financial analysis contract with GENFIT.
BIZARRE bizarre
le CIC est censé assurer la liquidité et est actionnaire mais le cours est coiffé.
Et si le CIC en était responsable dans le but de ramasser à bas prix ?
A suivre...
Investors marketing services to Genfit. Crédit Mutuel-
CM11 Group holds over 0,5% of GENFIT. CIC has
signed a financial analysis contract with GENFIT.
BIZARRE bizarre
le CIC est censé assurer la liquidité et est actionnaire mais le cours est coiffé.
Et si le CIC en était responsable dans le but de ramasser à bas prix ?
A suivre...
|
Répondre
|
? pas si vite ..... temporiser !!
|
Répondre
|
Objectif du CMCIC : 196 € !
GENFIT objectit de l'analyse CIC : 196€
Prospective val. 2021 (€) 196.0
Present value (€) 56.0
Entry point (€) 37.0
Price (€) 23.7
Closing at 10/04/2018
Bloomberg ticker GNFT FP
Market cap. (M€) 737
12/17 12/18e 12/19e
Sales (EURm) 7 6 5
EBIT (EURm) -57 -39 -36
EBIT margin (%) ns ns ns
EBIT (adj) (EURm) -57 -39 -36
Net Profit (adj.) (EURm) -59 -45 -42
EPS adjusted (EUR) -1.57 -1.22 -1.12
Revision (%) 5.9 8.9 10.5
Leverage (x) 2.1 1.9 0.8
EV/EBIT (adj.)(x) ns ns ns
P/E (adj.)(x) ns ns ns
Dividend yield (%) 0.0 0.0 0.0
Recruitment of Phase 3 patients finalised!
The facts: Genfit this morning announced that it has completed recruitment of the first 1,000 patients for its RESOLVE-IT Phase 3 trial in NASH.
Our analysis: The RESOLVE-IT Phase 3 trial is aimed at evaluating the efficacy and safety of elafibranor 120mg once daily in patients with NASH and fibrosis after 72 weeks of treatment. The patients are included after biopsy. The primary endpoint of the trial is resolution of NASH (ballooning: 0; inflammation: 0-1) without aggravation of the fibrosis. Based on the results obtained on the first 1,000 patients, Genfit could obtain early marketing authorisation for elafibranor, due to the high unsatisfied medical need for this disease. The company has taken heed to enroll patients from different regions (North America, Europe, etc.) in order to have the most representative sample of the population. Out of the first 1,000 patients in this Phase 3 trial, 48% have type 2 diabetes, 59% hypertension, and 51% dyslipidemia. The average BMI is 34.
Note that the company had cash of EUR274m at 31 December 2017 thanks to a EUR180m convertible bond issue (OCEANE) carried out in October 2017. In our view, this offers Genfit visibility out to 2021.
Conclusion & Action: Very good news for Genfit, which has crossed a major threshold. The results of this study are expected in Q3-2019. The next clinical news will be the result of the elafibranor phase 2 in PBC (end-2018).
GENFIT objectit de l'analyse CIC : 196€
Prospective val. 2021 (€) 196.0
Present value (€) 56.0
Entry point (€) 37.0
Price (€) 23.7
Closing at 10/04/2018
Bloomberg ticker GNFT FP
Market cap. (M€) 737
12/17 12/18e 12/19e
Sales (EURm) 7 6 5
EBIT (EURm) -57 -39 -36
EBIT margin (%) ns ns ns
EBIT (adj) (EURm) -57 -39 -36
Net Profit (adj.) (EURm) -59 -45 -42
EPS adjusted (EUR) -1.57 -1.22 -1.12
Revision (%) 5.9 8.9 10.5
Leverage (x) 2.1 1.9 0.8
EV/EBIT (adj.)(x) ns ns ns
P/E (adj.)(x) ns ns ns
Dividend yield (%) 0.0 0.0 0.0
Recruitment of Phase 3 patients finalised!
The facts: Genfit this morning announced that it has completed recruitment of the first 1,000 patients for its RESOLVE-IT Phase 3 trial in NASH.
Our analysis: The RESOLVE-IT Phase 3 trial is aimed at evaluating the efficacy and safety of elafibranor 120mg once daily in patients with NASH and fibrosis after 72 weeks of treatment. The patients are included after biopsy. The primary endpoint of the trial is resolution of NASH (ballooning: 0; inflammation: 0-1) without aggravation of the fibrosis. Based on the results obtained on the first 1,000 patients, Genfit could obtain early marketing authorisation for elafibranor, due to the high unsatisfied medical need for this disease. The company has taken heed to enroll patients from different regions (North America, Europe, etc.) in order to have the most representative sample of the population. Out of the first 1,000 patients in this Phase 3 trial, 48% have type 2 diabetes, 59% hypertension, and 51% dyslipidemia. The average BMI is 34.
Note that the company had cash of EUR274m at 31 December 2017 thanks to a EUR180m convertible bond issue (OCEANE) carried out in October 2017. In our view, this offers Genfit visibility out to 2021.
Conclusion & Action: Very good news for Genfit, which has crossed a major threshold. The results of this study are expected in Q3-2019. The next clinical news will be the result of the elafibranor phase 2 in PBC (end-2018).
|
Répondre
|
Suivez les marchés avec des outils de pros !